heterozygous familial hypercholesterolaemia
Cardiovascular · 2005–2019
5decisions
4medicines
3carried consumer input
37individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| alirocumab Treatment of heterozygous familial hypercholesterolaemia (he-FH) in patients with atherosclerotic disease or very high LDL levels, and non-familial… | Mar 2019 | Recommended with restriction | 6 individuals Familial Hypercholesterolaemia Family Support Group |
| evolocumab Treatment of heterozygous familial hypercholesterolaemia with atherosclerotic disease or very high LDL-cholesterol levels, and non-familial… | Nov 2017 | Deferred | 18 individuals |
| alirocumab Treatment of heterozygous familial hypercholesterolaemia (HeFH) and clinical atherosclerotic cardiovascular disease (ASCVD) in patients with inadequate control… | Nov 2017 | Not recommended | 13 individuals |
| ezetimibe Addition of two indications to the current listing for ezetimibe, namely peripheral vascular disease and heterozygous familial hypercholesterolaemia, on the… | Nov 2005 | Recommended with restriction | no section in document |
| ezetimibe; ezetimibe with simvastatin Addition of symptomatic peripheral vascular disease and heterozygous familial hypercholesterolaemia to the ezetimibe listing for co-administration with a… | Nov 2005 | Recommended with restriction | no section in document |
Who spoke
Familial Hypercholesterolaemia Family Support Group
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.